Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ubamatamab

A bispecific, human monoclonal antibody with potential antineoplastic activity. REGN4018 contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen that is part of the T-cell receptor complex, and one for human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), a member of the mucin family of glycoproteins that is overexpressed by several epithelial cancers, including ovarian cancer. Upon administration, ubamatamab binds to both T cells and MUC16-expressing tumor cells, which cross-links the T cells to the tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against the MUC16-expressing tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-MUC16 x anti-CD3 REGN4018
anti-MUC16/CD3 bispecific antibody REGN4018
bispecific T-cell engager antibody REGN4018
MUC16/CD3-directed bispecific T-cell engager antibody REGN4018
MUC16xCD3 bispecific T-cell engager REGN4018
Code name:REGN 4018
REGN-4018
REGN4018
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search